Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: To appraise the role of stereotactic body radiation therapy (SBRT) in patients with lung metastasis from primary soft tissue sarcoma. Methods: Twenty-eight patients (51 lesions) were analysed. All patients were in good performance status (1-2 eastern cooperative oncology group (ECOG)), unsuitable for surgical resection, with controlled primary tumour and the number of lung metastases was ≤4. In a risk adaptive scheme, the dose prescription was: 30 Gy/1 fr, 60 Gy/3 fr, 60 Gy/8 fr and 48 Gy/4 fr. Treatments were performed with Volumetric Modulated Arc Therapy. Clinical outcome was evaluated by thoracic and abdominal computed tomography (CT) scan before SBRT and than every 3 months. Toxicity was evaluated with Common Terminology Criteria for Adverse Events (CTCAE) scale version 4.0. Results: Leiomyosarcoma (36%) and synovial sarcoma (25%) were the most common histologies. Five patients (18%) initially presented with pulmonary metastasis, whereas 23 (82%) developed them at a median time of 51 months (range 11-311 months) from the initial diagnosis. The median follow-up time from initial diagnosis was 65 months (5-139 months) and from SBRT was 21 months (2-80 months). No severe toxicity (grades III-IV) was recorded and no patients required hospitalisation. The actuarial 5-years local control rate (from SBRT treatment) was 96%. Overall survival at 2 and 5 years was 96.2% and 60.5%, respectively. At last follow-up 15 patients (54%) were alive. All other died because of distant progression. Conclusions: SBRT provides excellent local control of pulmonary metastasis from soft tissue sarcoma (STS) and may improve survival in selected patients. SBRT should be considered for all patients with pulmonary metastasis (PM) and evaluated in a multidisciplinary team.

Original languageEnglish
Pages (from-to)668-674
Number of pages7
JournalEuropean Journal of Cancer
Volume51
Issue number5
DOIs
Publication statusPublished - Feb 13 2015

Fingerprint

Sarcoma
Radiotherapy
Neoplasm Metastasis
Lung
Synovial Sarcoma
Intensity-Modulated Radiotherapy
Survival
Leiomyosarcoma
Terminology
Prescriptions
Histology
Hospitalization
Thorax
Tomography
Therapeutics
Neoplasms

Keywords

  • Lung
  • RapidArc
  • Soft tissue sarcoma
  • Stereotactic body radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

@article{b1fdaa2f3ba04b09a560eae55fdffe5a,
title = "Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma",
abstract = "Purpose: To appraise the role of stereotactic body radiation therapy (SBRT) in patients with lung metastasis from primary soft tissue sarcoma. Methods: Twenty-eight patients (51 lesions) were analysed. All patients were in good performance status (1-2 eastern cooperative oncology group (ECOG)), unsuitable for surgical resection, with controlled primary tumour and the number of lung metastases was ≤4. In a risk adaptive scheme, the dose prescription was: 30 Gy/1 fr, 60 Gy/3 fr, 60 Gy/8 fr and 48 Gy/4 fr. Treatments were performed with Volumetric Modulated Arc Therapy. Clinical outcome was evaluated by thoracic and abdominal computed tomography (CT) scan before SBRT and than every 3 months. Toxicity was evaluated with Common Terminology Criteria for Adverse Events (CTCAE) scale version 4.0. Results: Leiomyosarcoma (36{\%}) and synovial sarcoma (25{\%}) were the most common histologies. Five patients (18{\%}) initially presented with pulmonary metastasis, whereas 23 (82{\%}) developed them at a median time of 51 months (range 11-311 months) from the initial diagnosis. The median follow-up time from initial diagnosis was 65 months (5-139 months) and from SBRT was 21 months (2-80 months). No severe toxicity (grades III-IV) was recorded and no patients required hospitalisation. The actuarial 5-years local control rate (from SBRT treatment) was 96{\%}. Overall survival at 2 and 5 years was 96.2{\%} and 60.5{\%}, respectively. At last follow-up 15 patients (54{\%}) were alive. All other died because of distant progression. Conclusions: SBRT provides excellent local control of pulmonary metastasis from soft tissue sarcoma (STS) and may improve survival in selected patients. SBRT should be considered for all patients with pulmonary metastasis (PM) and evaluated in a multidisciplinary team.",
keywords = "Lung, RapidArc, Soft tissue sarcoma, Stereotactic body radiation therapy",
author = "Pierina Navarria and Ascolese, {Anna Maria} and Luca Cozzi and Stefano Tomatis and D'Agostino, {Giuseppe Roberto} and {De Rose}, Fiorenza and {De Sanctis}, Rita and Andrea Marrari and Armando Santoro and Antonella Fogliata and Umberto Cariboni and Marco Alloisio and Vittorio Quagliuolo and Marta Scorsetti",
year = "2015",
month = "2",
day = "13",
doi = "10.1016/j.ejca.2015.01.061",
language = "English",
volume = "51",
pages = "668--674",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "5",

}

TY - JOUR

T1 - Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma

AU - Navarria, Pierina

AU - Ascolese, Anna Maria

AU - Cozzi, Luca

AU - Tomatis, Stefano

AU - D'Agostino, Giuseppe Roberto

AU - De Rose, Fiorenza

AU - De Sanctis, Rita

AU - Marrari, Andrea

AU - Santoro, Armando

AU - Fogliata, Antonella

AU - Cariboni, Umberto

AU - Alloisio, Marco

AU - Quagliuolo, Vittorio

AU - Scorsetti, Marta

PY - 2015/2/13

Y1 - 2015/2/13

N2 - Purpose: To appraise the role of stereotactic body radiation therapy (SBRT) in patients with lung metastasis from primary soft tissue sarcoma. Methods: Twenty-eight patients (51 lesions) were analysed. All patients were in good performance status (1-2 eastern cooperative oncology group (ECOG)), unsuitable for surgical resection, with controlled primary tumour and the number of lung metastases was ≤4. In a risk adaptive scheme, the dose prescription was: 30 Gy/1 fr, 60 Gy/3 fr, 60 Gy/8 fr and 48 Gy/4 fr. Treatments were performed with Volumetric Modulated Arc Therapy. Clinical outcome was evaluated by thoracic and abdominal computed tomography (CT) scan before SBRT and than every 3 months. Toxicity was evaluated with Common Terminology Criteria for Adverse Events (CTCAE) scale version 4.0. Results: Leiomyosarcoma (36%) and synovial sarcoma (25%) were the most common histologies. Five patients (18%) initially presented with pulmonary metastasis, whereas 23 (82%) developed them at a median time of 51 months (range 11-311 months) from the initial diagnosis. The median follow-up time from initial diagnosis was 65 months (5-139 months) and from SBRT was 21 months (2-80 months). No severe toxicity (grades III-IV) was recorded and no patients required hospitalisation. The actuarial 5-years local control rate (from SBRT treatment) was 96%. Overall survival at 2 and 5 years was 96.2% and 60.5%, respectively. At last follow-up 15 patients (54%) were alive. All other died because of distant progression. Conclusions: SBRT provides excellent local control of pulmonary metastasis from soft tissue sarcoma (STS) and may improve survival in selected patients. SBRT should be considered for all patients with pulmonary metastasis (PM) and evaluated in a multidisciplinary team.

AB - Purpose: To appraise the role of stereotactic body radiation therapy (SBRT) in patients with lung metastasis from primary soft tissue sarcoma. Methods: Twenty-eight patients (51 lesions) were analysed. All patients were in good performance status (1-2 eastern cooperative oncology group (ECOG)), unsuitable for surgical resection, with controlled primary tumour and the number of lung metastases was ≤4. In a risk adaptive scheme, the dose prescription was: 30 Gy/1 fr, 60 Gy/3 fr, 60 Gy/8 fr and 48 Gy/4 fr. Treatments were performed with Volumetric Modulated Arc Therapy. Clinical outcome was evaluated by thoracic and abdominal computed tomography (CT) scan before SBRT and than every 3 months. Toxicity was evaluated with Common Terminology Criteria for Adverse Events (CTCAE) scale version 4.0. Results: Leiomyosarcoma (36%) and synovial sarcoma (25%) were the most common histologies. Five patients (18%) initially presented with pulmonary metastasis, whereas 23 (82%) developed them at a median time of 51 months (range 11-311 months) from the initial diagnosis. The median follow-up time from initial diagnosis was 65 months (5-139 months) and from SBRT was 21 months (2-80 months). No severe toxicity (grades III-IV) was recorded and no patients required hospitalisation. The actuarial 5-years local control rate (from SBRT treatment) was 96%. Overall survival at 2 and 5 years was 96.2% and 60.5%, respectively. At last follow-up 15 patients (54%) were alive. All other died because of distant progression. Conclusions: SBRT provides excellent local control of pulmonary metastasis from soft tissue sarcoma (STS) and may improve survival in selected patients. SBRT should be considered for all patients with pulmonary metastasis (PM) and evaluated in a multidisciplinary team.

KW - Lung

KW - RapidArc

KW - Soft tissue sarcoma

KW - Stereotactic body radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84924422756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924422756&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2015.01.061

DO - 10.1016/j.ejca.2015.01.061

M3 - Article

C2 - 25686482

AN - SCOPUS:84924422756

VL - 51

SP - 668

EP - 674

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 5

ER -